Moderna surges after hours on patent settlement with Arbutus and Genevant
Source: SeekingAlpha
2026-03-03 17:16:52 ET
More on Moderna
- Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
- Moderna, Inc. 2025 Q4 - Results - Earnings Call Presentation
- EMA recommends authorization of Moderna combination COVID/flu vaccine
- CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
Read the full article on Seeking Alpha
For further details see:
Moderna surges after hours on patent settlement with Arbutus and Genevant
Roivant Sciences Ltd.
NASDAQ: ROIV
ROIV Trading
2.36% G/L:
$29.25 Last:
2,894,020 Volume:
$28.59 Open:
ROIV Latest News
March 04, 2026 11:42:41 pm
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
ROIV Stock Data
$19,574,426,097
449,460,314
0.77%
170
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
